Clinical Trial Update: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing eribulin plus gemcitabine vs paclitaxel plus gemcitabine in HER2-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• eribulin plus gemcitabine
• paclitaxel plus gemcitabine

Snippet

Sponsor: Asan Medical Center | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED